Zenrelia™ gets nearly 50% more itchy dogs back to normal than Apoquel®1††
Watch the video to find out more about Zenrelia
Proven Itch Relief
Back to normalZenrelia (Ilunocitinib) gets nearly 50% more itchy dogs back to normal than to Apoquel (Oclacitinib)1††
Once-daily dosingSimple, consistent dosing from the start2
Itch controlZenrelia delivers 24-hour itch relief 1,3
Safety profileSafety profile comparable to Apoquel1
Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.‡
What do dog owners want?
79% of owners expect their dog to be back to normal when they treat their itch10. The reality is a little different, with only 53% of dogs treated with Apoquel getting back to normal.1,**
Zenrelia gets nearly 50% more itchy dogs back to normal vs Apoquel1††
Proportion of itchy dogs getting back to normal
A 'normal' itch score is considered to be comparable to that of a healthy, non-allergenic dog (PVAS <2).1
Veterinary experts rate Zenrelia
"Allergies are going to remain with us for the rest of our lives, so to have an additional drug that helps those patients suffering from atopic dermatitis, or from itchiness, or from allergy is very, very exciting, because obviously it makes the dogs happier, the owners more grateful and our lives as veterinary surgeons more rewarding. Would I prescribe Zenrelia? Definitely, I can't wait to prescribe it!"
Prof Anette Loeffler DrMedVet, PhD, DVD, DipECVD, FHEA MRCVS
Professor in Veterinary Dermatology
“The veterinary community should be really excited about Zenrelia, because we haven't had any new developments or drug options to manage our cases of atopic dermatitis for quite some time. So this is really bringing something new and innovative to help us manage this really chronic disease that we see of atopic dermatitis that not only effects dogs’ quality of life, but also it affects owners’ quality of life as well.”
Dr Natalie Barnard BVetMed, CertVD, DipECVD, MRCVS
RCVS and European Specialist in Veterinary Dermatology
What is Zenrelia?
Zenrelia is a NEW JAK inhibitor containing ilunocitinib for dogs with allergic and atopic dermatitis.
It treats:
Questions?
Zenrelia Resources
*Referenceable claims in digital and social copy can be found on this page. Full reference list below.
†† 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).1
‡ Based on list price of Zenrelia as of 07/25 vs other licensed JAK inhibitors for dogs.
** Proportion of dogs treated with Apoquel achieving a PVAS <2 by day 112.1
- Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176.
- Zenrelia Summary of Product Characteristics.
- Unpublished data: Owner Pruritus Assessment (PVAS) form.
- Gedon NKY, Mueller RS. Clin Transl Allergy. 2018 Oct; 8:41.
- Bond R et al. Vet Rec. 2007 Apr; 160:503–6.
- Unpublished data (107): Field Study for Control of Pruritus Associated with Allergic Dermatitis.
- Olivry T, Mueller RS. BMC Vet Res. 2017 Feb;13(1):51.
- Mueller RS et al. BMC Vet Res. 2016 Jan; 12:9.
- Mason K et al. Vet Dermatol. 2023 May; 34:115–24.
- Rybnícek J et al. Vet Dermatol. 2009 Apr; 20(2):115-22.
